What is IO Biotech Earnings Power Value (EPV)?
As of Mar24, IO Biotech's earnings power value is $1.76. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
IO Biotech Earnings Power Value (EPV) Historical Data
The historical data trend for IO Biotech's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IO Biotech Earnings Power Value (EPV) Chart
|
IO Biotech Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Earnings Power Value (EPV) |
|
- |
- |
- |
- |
- |
|
IO Biotech Quarterly Data
|
|
Dec19 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of IO Biotech's Earnings Power Value (EPV)
For the Biotechnology subindustry, IO Biotech's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IO Biotech's Earnings Power Value (EPV) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IO Biotech's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where IO Biotech's Earnings Power Value (EPV) falls into.
IO Biotech Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
IO Biotech (IO Biotech) Business Description
Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen N, DNK, DK-2200
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Executives
| Brian Burkavage |
officer: Chief Accounting Officer |
C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103 |
| Heidi Hunter |
director |
C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080 |
| Partners Kurma |
10 percent owner |
24 RUE ROYALE, PARIS I0 75008 |
| Novo Holdings A/s |
10 percent owner |
TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
| Vivo Opportunity Fund Holdings, L.p. |
10 percent owner |
192 LYTTON AVENUE, PALO ALTO CA 94301 |
| Devin Whittemore Smith |
officer: General Counsel |
C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451 |
| Vivo Capital Fund Ix, L.p. |
10 percent owner |
192 LYTTON AVENUE, PALO ALTO CA 94301 |
| Vivo Opportunity, Llc |
10 percent owner |
192 LYTTON AVENUE, PALO ALTO CA 94301 |
| Qasim Iftikhar Ahmad |
officer: Chief Medical Officer |
1209 ORANGE STREET, WILMINGTON DE 19801 |
| Amy Sullivan |
officer: Chief Financial Officer |
38 OUTLOOK ROAD, SWAMPSCOTT MA 01907 |
| David V Smith |
director |
6035 STONERIDGE DRIVE, PLEASANTON CA 94588 |
| Lundbeckfond Invest A/s |
10 percent owner |
SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100 |
| Jack Nielsen |
director |
C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142 |
| Vanessa Malier |
director |
1209 ORANGE STREET, WILLMINGTON DE 19801 |
| Claus A. Andersson |
director |
1209 ORANGE STREET, WILMINGTON DE 19801 |
IO Biotech (IO Biotech) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IOBT has been successfully added to your